Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Investigational Cell Therapy Beyond Oncology: Education, Communication, and Lessons Learned from Utilizing a Centralized Oncology Based Cell Therapy Program

Neil Bailey, Tenzin Tsomo, Jordan Briggs, Tori Braun, Krystle Pagarigan, Morgan Hanson, Phuong Nam Doan, Kory Barrow, Wezi Longwe, Rachael Crickman, Evonne Lackey, Swathi Namburi, Matthew Schwede, Krish Patel

Blood (2024) 144 (Supplement 1): 7956.

https://doi.org/10.1182/blood-2024-208076

Published: 2024

Journal Articles

Updated Response and Safety for Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Neil Bailey, Tori Braun, Megumi Bailey, Tenzin Tsomo, Jennie Szeto, Swathi Namburi, Joanna Fesler, Sonia Glennie, Vanessa Dunleavy, Julia Carolyn Bokma Parker, Gayle Funk, Heidi Hohmann, Chiachun Lu, Jordan Briggs, Krish Patel

Blood (2024) 144 (Supplement 1): 3111.

https://doi.org/10.1182/blood-2024-209252

Published: 2024

Journal Articles

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Blood (2024) 144 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2024-199733

Published: 2024

Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Blood (2023) 142 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2023-179170

Published: 2023

Journal Articles

A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL

Graham P. Collins, William Townsend, Ahmed Abdulgawad, Swathi Namburi, Anja Williams, Ana Filipa Palma DosReis, Matthew G. Krebs, Jeff Evans, Sarah P. Blagden, Ruth Plummer, Daniel Hochhauser, Adam Sharp, George Cole, Seema Rogers, Daniel Chan, Sarah Whelan, Dima El-Sharkawi

Blood (2023) 142 (Supplement 1): 3093.

https://doi.org/10.1182/blood-2023-172875

Published: 2023

Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Blood (2023) 142 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2023-177968

Published: 2023

Journal Articles

Characteristics of a Comprehensive, Continuously Updated Longitudinal Database for Multiple Myeloma

Blood (2021) 138 (Supplement 1): 4969.

https://doi.org/10.1182/blood-2021-148399

Published: 2021

Journal Articles

Variation in the Treatment of Multiple Myeloma in the Real World

Joshua Richter, MD, Leena Chhun, B.S., Cheng Zheng, B.S., Jayne Piboonvaranggoon, B.S., Elora Mallick, B.S., Jennifer Wren, B.S., Grace Nam, M.S., Ricardo Lopez Barquilla, PhD, Alexandra Dardac, B.S., Sibel Blau, MD, Francis M. Senecal, MD, Swathi Namburi, MD, Andrew J. Cowan, MD, William I Bensinger, MD, Shaji K. Kumar, MD, Paul G. Richardson, MD, Kenneth Anderson, MD, C. Anthony Blau, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-138705

Published: 2020

Journal Articles

Persistence of Exosomes in Patients with Acute Myeloid Leukemia in Complete Remission Suppresses Hematopoiesis

Swathi Namburi, MD, Hal E. Broxmeyer, PhD, Theresa L Whiteside, PhD, Michael Boyiadzis, MD

Blood (2018) 132 (Supplement 1): 3850.

https://doi.org/10.1182/blood-2018-99-115354

Published: 2018

Journal Articles

Plasma-Derived Exosomes in Acute Myeloid Leukemia Carry Dipeptidylpeptidase-4 and Inhibit Normal Human Hematopoiesis

Swathi Namburi, Hal E. Broxmeyer, PhD, Theresa L Whiteside, PhD, Michael Boyiadzis, MD

Blood (2017) 130 (Supplement 1): 1164.

https://doi.org/10.1182/blood.V130.Suppl_1.1164.1164

Published: 2017

Journal Articles

Location Matters in Nodal Diffuse Large B-Cell Lymphoma

Konstantinos Lontos, MD, Anastasia Tsagianni, MD, Swathi Namburi, Arpita Gandhi, MD BA, Jian-Min Yuan, MD PhD, Daniel Normolle, PhD, Michael Boyiadzis, MD, Steven H. Swerdlow, MD, Kathleen A. Dorritie, MD

Blood (2017) 130 (Supplement 1): 2854.

https://doi.org/10.1182/blood.V130.Suppl_1.2854.2854

Published: 2017

NARROW

Investigational Cell Therapy Beyond Oncology: Education, Communication, and Lessons Learned from Utilizing a Centralized Oncology Based Cell Therapy Program

Updated Response and Safety for Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Characteristics of a Comprehensive, Continuously Updated Longitudinal Database for Multiple Myeloma

Variation in the Treatment of Multiple Myeloma in the Real World

Persistence of Exosomes in Patients with Acute Myeloid Leukemia in Complete Remission Suppresses Hematopoiesis

Plasma-Derived Exosomes in Acute Myeloid Leukemia Carry Dipeptidylpeptidase-4 and Inhibit Normal Human Hematopoiesis

Location Matters in Nodal Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only